权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cross-sectional and prospective cohort data analysis of physical activity and hea

身体活动和健康的横断面和前瞻性队列数据分析

基本信息

批准号：
8089436
负责人：
PAUL T WILLIAMS
金额：
$ 37.16万
依托单位：
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-01 至 2014-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8089436
关键词：
Aerobic Affect American American Heart Association Baseline Surveys Benign Prostatic Hypertrophy Body Size Body Weight Breast Cardiovascular Diseases Cataract Cause of Death Cessation of life Collection Colon Data Data Analyses Diabetes Mellitus Diagnosis Disease Dose Exercise Female Frequencies Gall Bladder Diseases Gout Grant Guidelines Health Health Benefit Hour Hypertension Injury Knowledge Macular degeneration Malignant Neoplasms Marathon Mediating Minority Myocardial Infarction Myocardial Ischemia Obesity Participant Performance Persons Physical activity Physicians Principal Investigator Prostate Public Health Publications Questionnaires Recommendation Recruitment Activity Reporting Request for Applications Retrieval Risk Risk Reduction Running Sample Size Sampling Science Sports Medicine Stroke Surveys Testing Time Training Update Wages Walkers Walking base cohort college experience falls fitness follow-up hypercholesterolemia indexing mortality physical conditioning prospective response

项目摘要

DESCRIPTION (provided by applicant): Current public health guidelines recommend moderate-intensity aerobic (endurance) physical activity for a minimum of 30 min on five days each week or vigorous-intensity aerobic physical activity for a minimum of 20 min on three days each week. The guidelines specifically acknowledge that the point of maximum benefit for most health benefits has not been established. Our initial 7.8-year follow-up of the National Runners' Health showed that exceeding the current guideline levels was associated with significantly lower risks of cataracts (35%), macular degeneration (54%), hypertension (30%), hypercholesterolemia (47%), diabetes (68%), gout (45%), gallbladder disease (52%), diverticular disease (48%), benign prostate hyperplasia (33%), and nonfatal stroke (60%). To further demonstrate the potential benefits of exceeding guideline activity levels, we propose to compare moderate-intensity (walking) and vigorous intensity physical activity (running) to total and cause- specific mortality in 45,685 participants of the National Walkers' Health Study and 59,165 participants of the second National Runners' Health Study who surveyed at baseline between 1998-2000, and 54,960 participants of the original National Runners' Health Study were surveyed at baseline between 1991 and 1993. We estimate that 26,172 deaths will have occurred during the two million person years of follow-up, including 863 fatal colon, 426 breast, and 501 prostate, and 8,030 total cancers, 5,714 ischemic heart disease deaths, and 2,259 fatal myocardial infarctions. Three-year support is requested to obtain and analyze the National Death Index retrieval of cause of death in order to: 1: Define separately within the walkers' (N=45,685) and the combined runners' cohort (N=114,719) the dose- response relationships of total and cause-specific mortality vs. the amount, duration, intensity, and frequency of physical activity. 2: Test whether equivalent doses (i.e., MET-hours) of moderate-intensity (walking, N=45,685) and vigorous- intensity activity (running, N=59,165) yield comparable reductions in total and cause-specific mortality. 3: Test within the combined runners' cohorts whether cardiorespiratory fitness significantly predicts total and cause-specific mortality independent of physical activity (N=84,120, representing 72% of the sample reporting 10-km performance times). 4: Test within the original runners' cohort (N=54,960) whether change in activity during the 7.8 years between the first and second survey affects total and cause-specific mortality during the subsequent 11-year follow-up. 5: Test separately within the walkers (N=45,685) and combined runners' cohorts (N=114,125) whether or longest usual walk or run (including marathon training) significantly predicts total and cause-specific mortality independent of usual physical activity. 6: Test whether body weight or size mediates the relationships and differences of aims 1-5. PUBLIC HEALTH RELEVANCE: Narrative This application requests salary support for the principal investigator to apply his 20 years of biostatistical experience to analyze a large cohort of walkers and runners to determine the health benefits of vigorous exercise, marathon participation, and interactions with other variables on cardiovascular disease, diabetes, hypertension, gout, gallbladder disease, benign prostatic hyperplasia and other health endpoints. This application is concerned exclusively with the interpretation of actual data and not the collection of new data. The major objective is to better define the dose and intensity of physical activity for optimal health.

描述（由申请人提供）：目前的公共卫生指南推荐每周5天至少30分钟的中等强度有氧（耐力）体力活动或每周3天至少20分钟的高强度有氧体力活动。该指南明确承认，大多数健康效益的最大效益点尚未确立。我们对国家跑步者健康的最初的8年随访显示，超过目前的指导水平与白内障（35%）、黄斑变性（54%）、高血压（30%）、高胆固醇血症（47%）、糖尿病（68%）、痛风（45%）、胆囊疾病（52%）、憩室疾病（48%）、良性前列腺增生（33%）和非致命性中风（60%）的风险显著降低相关。为了进一步证明超过指南活动水平的潜在益处，我们建议比较中等强度（步行）和剧烈强度体力活动（跑步）对总死亡率和特定原因死亡率的影响，研究对象为45,685名全国步行者健康研究参与者和59,165名1998-2000年间基线调查的第二次全国跑步者健康研究参与者。在1991年至1993年期间，对54,960名最初的国家跑步者健康研究参与者进行了基线调查。我们估计，在200万人的随访期间，将发生26172例死亡，其中包括863例致命的结肠癌、426例乳腺癌和501例前列腺癌，以及8030例癌症，5714例缺血性心脏病死亡和2259例致命的心肌梗死。为获取和分析国家死亡指数死因检索，需要三年的支持，以便：1：分别在步行者（N=45,685）和联合跑步者队列（N=114,719）中定义总死亡率和原因特异性死亡率与体力活动的数量、持续时间、强度和频率之间的剂量-反应关系。2：测试中等强度（步行，N=45,685）和剧烈运动（跑步，N=59,165）的同等剂量（即met -小时）是否能在总死亡率和原因特异性死亡率方面产生可比的降低。3：在联合跑步者队列中测试心肺健康是否显著预测独立于身体活动的总死亡率和原因特异性死亡率（N=84,120，代表报告10公里运动时间的样本的72%）。4：在最初的跑步者队列（N=54,960）中测试，在第一次和第二次调查之间的7.8年中，运动的变化是否会影响随后11年随访期间的总死亡率和原因特异性死亡率。5：分别在步行者组（N=45,685）和联合跑步组（N=114,125）中进行测试，通常最长的步行或跑步（包括马拉松训练）是否能显著预测独立于通常身体活动的总死亡率和病因特异性死亡率。6：检验体重或体型是否在目标1-5的关系和差异中起中介作用。本申请要求首席研究者运用其20年的生物统计学经验来分析一大批步行者和跑步者，以确定剧烈运动、马拉松参与以及与心血管疾病、糖尿病、高血压、痛风、胆囊疾病、良性前列腺增生和其他健康终点的其他变量的相互作用对健康的益处。这个应用程序只关心实际数据的解释，而不关心新数据的收集。主要目标是更好地确定身体活动的剂量和强度，以达到最佳健康状态。